Inside information pursuant to Article 17 MAR
FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
Heidelberg Pharma AG today announced that the US Food and Drug Administration (FDA) has informed the company it is safe to proceed with the Phase I/IIa study with the BCMA Antibody Targeted Amanitin Conjugate, HDP-101 that was submitted under its US IND. The study will evaluate HDP- 101 for the treatment of multiple myeloma, a blood cancer with high unmet medical need.